Immunostimulating Complex adjuvant (ISCOM)

Immunostimulating Complex (ISCOM) adjuvants are particulate nanostructures composed of cholesterol, phospholipids, and saponins (such as Quil-A), designed to deliver antigens and stimulate robust cellular and humoral immune responses. They function by enhancing antigen presentation to APCs, promoting dendritic cell maturation, and inducing a cytokine environment conducive to both antibody and cytotoxic T cell (CTL) responses. ISCOM-type adjuvants have been used in veterinary and experimental human vaccines, with demonstrated utility against a variety of infectious agents and tumors. They differ from molecular therapeutic targets in that they are not single proteins or receptors, but structured complexes used to boost vaccine efficacy[1][2][3].

Other names

ISCOM adjuvantISCOMATRIXImmunostimulating ComplexISCOM-type adjuvant

Enhances immunogenicity by: - Facilitating antigen uptake by antigen-presenting cells (APCs)[1][2] - Promoting maturation and IL-12 secretion by dendritic cells[2] - Fostering both humoral (antibody) and cellular (T cell, CTL) immunity, balancing Th1/Th2 responses[1][2][3] - Engaging inflammasome pathways (e.g., NLRP3/caspase-1)[2]